BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS
Bio-Techne appointed Dr. Judith Klimovsky as an independent director on the Board of Directors, bringing valuable experience from the biotechnology industry.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne appointed Dr. Judith Klimovsky as an independent director on the Board of Directors, bringing valuable experience from the biotechnology industry. Dr. Klimovsky's background in antibody therapeutics and global clinical development positions her well to contribute to Bio-Techne's expansion efforts. The addition of Dr. Klimovsky enhances the board's expertise and diversity, with a focus on Latin America and global biopharma.
Positive
Dr. Judith Klimovsky's appointment adds valuable scientific and international experience to Bio-Techne's board.
Dr. Klimovsky's background in antibody therapeutics and extensive global biopharma experience will benefit Bio-Techne's development initiatives.
The temporary expansion of Bio-Techne's board to include Dr. Klimovsky highlights the company's commitment to enhancing its leadership team with diverse expertise.
Negative
- None.
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was -2.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various senior global clinical and research positions at Novartis Oncology, a division of Novartis AG, including SVP & Global Head, Oncology Clinical Development. Dr. Klimovsky also served as Regional Medical Director,
Dr. Klimovsky previously (from 2018 to Feb 2024) served as a Director of Bellicum Pharmaceuticals, a company discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors.
"We are pleased to welcome Dr. Klimovsky to our board," said Bob Baumgartner, Chairman of the Board of Bio-Techne. "She brings tremendous scientific and international experience, including running large development groups at global biopharma companies. She also has extensive experience in
About Bio-Techne Corporation (NASDAQ: TECH)
Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-appoints-dr-judith-klimovsky-to-board-of-directors-302129811.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.